Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czechia.
Institute of Microbiology, Academy of Sciences, Prague, Czechia.
Front Immunol. 2023 Jan 9;13:1038328. doi: 10.3389/fimmu.2022.1038328. eCollection 2022.
Probiotic administration seems to be a rational approach to promote maturation of the neonatal immune system. Mutual interaction of the microbiota with the host immune system is critical for the setting of appropriate immune responses including a tolerogenic one and thevmaintenance of homeostasis. On the other hand, our knowledge on the modes of actions of probiotics is still scarce.
In our study, probiotic strain Escherichia coli O83:K24:H31 (EcO83) was administered to neonates of allergic mothers (AMs; neonates with increased risk for allergy development) within 48 h after the delivery, and the impact of this early postnatal supplementation on allergy incidence and selected immune markers has been analyzed 10 years after the primary EcO83 administration.
We have observed decreased allergy incidence in 10-year-old children supplemented with EcO83 (13 of 52 children were allergic) in comparison with non-supplemented children of AMs (16 of 42 children were allergic). The early postnatal EcO83 supplementation appeared to limit the allergy in the high-risk group (children of AMs) compared to that in the low-risk group (children of healthy mothers). Dendritic cells (DCs) in the peripheral blood of EcO83-supplemented children do not differ significantly in cell surface presence of CD83. The immunomodulatory capacity of EcO83 on DCs was tested in vitro as well. Both directly isolated myeloid and in vitro monocyte-derived DCs from cord blood increased CD83 expression together with interleukin (IL)-10 secretion after EcO83 stimulation. The effect of early postnatal EcO83 supplementation on the microbiota composition of 10-year-old children was characterized by next-generation sequencing, and we have not observed significant changes in the microbiota composition of EcO83-supplemented and non-supplemented children at the age of 10 years.
Early postnatal EcO83 supplementation appears to lower allergy incidence in children of AMs. It seems that the beneficial effect of EcO83 is mediated via modulation of DC functional capacities without impacting the microbiota composition. Larger-scale studies will be necessary to confirm these preliminary findings.
益生菌的应用似乎是促进新生儿免疫系统成熟的合理方法。微生物群与宿主免疫系统的相互作用对于适当的免疫反应的建立至关重要,包括耐受原性和体内平衡的维持。另一方面,我们对益生菌作用模式的了解仍然有限。
在我们的研究中,在分娩后 48 小时内,将过敏母亲(AM;过敏发展风险增加的新生儿)的新生儿给予益生菌菌株大肠杆菌 O83:K24:H31(EcO83),并分析了 10 年后这种早期产后补充对过敏发生率和选定免疫标志物的影响。
与未补充 AM 儿童(42 名儿童中有 16 名过敏)相比,补充 EcO83 的 10 岁儿童过敏发生率降低(52 名儿童中有 13 名过敏)。与低风险组(健康母亲的儿童)相比,早期产后 EcO83 补充似乎限制了高风险组(AM 的儿童)的过敏。外周血树突状细胞(DC)表面 CD83 的存在无明显差异。还在体外测试了 EcO83 对 DC 的免疫调节能力。从脐带血中直接分离的髓样和体外单核细胞衍生的 DC 在 EcO83 刺激后均增加了 CD83 的表达和白细胞介素(IL)-10 的分泌。通过下一代测序描述了早期产后 EcO83 补充对 10 岁儿童微生物组组成的影响,并且在 10 岁时,我们没有观察到 EcO83 补充和未补充儿童的微生物组组成有明显变化。
早期产后 EcO83 补充似乎降低了 AM 儿童的过敏发生率。EcO83 的有益作用似乎是通过调节 DC 功能能力而不是影响微生物组组成来介导的。需要更大规模的研究来证实这些初步发现。